Abstract
We read with interest the April 2022 JADPRO meeting report article, “Molecular Testing in Hematologic Malignancies”, as presented by Laura Zitella, MS, RN, ACNP-BC, AOCN®. We were pleased that Ms. Zitella chose to share information about biomarker testing, a topic that is frequently not addressed nor well understood by advanced practitioners. We would however like to call attention to a significant error in describing nonsense variants and highlight a transition in using the term “variant” to replace “mutation”.
